Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: A study in China

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 161-170

  Tang, Shenjie ^a,b   Yao, Lan ^b   Hao, Xiaohui ^b   Zhang, Xia ^c   Liu, Gang ^d   Liu, Xin ^e   Wu, Meiying ^f   Zen, Linhai ^b   Sun, Hua ^g   Liu, Yidian ^b   Gu, Jin ^b   Lin, Feishen ^c   Wang, Xiafang ^f   Zhang, Zhanjun ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c NANJING CHEST HOSPITAL   (China)

^d Anhui Province Chest Hospital   (China)

^e Henan Chest Hospital   (China)

^f The Affiliated Infectious Diseases Hospital of Soochow University   (China)

^g Shanghai Minhang District Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; CHINA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEATH; DIRECTLY OBSERVED THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEMOPTYSIS; HUMAN; HYPOKALEMIA; LEUKOPENIA; LIVER INJURY; LUNG CAVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TINNITUS; VOMITING; ADOLESCENT; CLINICAL TRIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; METABOLISM; PROSPECTIVE STUDY; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CHINA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; LINEZOLID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPUTUM; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920586166     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00035114     Document Type: Article

References (39)

1. World Health Organization. Global Tuberculosis Report 2012. Geneva, World Health Organization, 2012.
2. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
3. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: Emergency Update 2008. Geneva, World Health Organization, 2008.
4. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
5. World Health Organization. Global Tuberculosis Report 2013. Geneva, World Health Organization, 2013.
6. World Health Organization. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva, World Health Organization, 2010.
7. National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis, Implementing Office of the Epidemiological Sampling Survey for Tuberculosis. [The prevalence of pulmonary tuberculosis in a national survey across China in 2010]. Zhonghua Jie He He Hu Xi Za Zhi 2012:35: 665-658.
8. Tang SJ, Zhang Q, Yu JM, et al. Extensively drug-resistant tuberculosis, China. Emerg Infect Dis 2011; 17: 558-560.
9. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
10. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant-TB outcomes. Eur Respir J 2013; 42: 156-168.
11. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169-179.
12. Brown-Elliott BA, Crist CJ, Mann LB, et al. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003; 47: 1736-1738.
13. Prammananan T, Chaiprasert A, Leechawengwongs M. In vitro activity of linezolid against multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR)-TB isolates. Int J Antimicrob Agents 2009; 33: 190-191.
14. Huang TS, Liu YC, Sy CL, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 2008; 52: 2226-2227.
15. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
16. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-704.
17. Fortún J, Martín-Dávila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
18. Singla R, Caminero JA, Jaiswal A, et al. Linezolid, an effective, safe and cheap drug in multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012; 39: 956-962.
19. Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187-192.
20. Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-783.
21. Tangg SJ, Zhang Q, Zeng LH, et al. Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis. Jpn J Infect Dis 2011; 64: 509-512.
22. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
23. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
24. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
25. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline; Guideline for Good Clinical Practice E6(R1) Current Step 4 Version. Geneva, ICH, 1996.
26. World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis: Fourth Edition. Geneva, World Health Organization, 2009.
27. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
28. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
29. Villar M, Sotgiu G, D'Ambrosio L, et al. Linezolid safety, tolerability and efficacy to treat multidrug-and extensively drug-resistant tuberculosis. Eur Respir J 2011; 38: 730-733.
30. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-A report of ten cases. J Infect 2006; 52: 92-96.
31. Nam HS, Koh WJ, Kwon OJ, et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009; 33: 92-93.
32. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
33. García-Tapia A, Rodriguez JC, Ruiz M, et al. Action of fluoroquinolones and linezolid on logarithmic-and stationary-phase culture of Mycobacterium tuberculosis. Chemotherapy 2004; 50: 211-213.
34. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
35. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR-and XDR-TB: an Indian perspective. Eur Respir J 2010; 35: 936-938.
36. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.
37. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
38. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
39. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.